Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Synthesis and Biological Activity of Benzoxazole Containing Thiazolidinedione Derivatives

  • Jeon, Ra-Ok (College of Pharmacy, Sookmyung Women′s University) ;
  • Park, So-Yeon (College of Pharmacy, Sookmyung Women s University)
  • Published : 2004.11.01
Download PDF
⟨ Previous Next ⟩

Abstract

The peroxisome proliferator-activated receptors (PPARs) are a primary regulator of lipid metabolism. Potency for activation of PPAR$\gamma$, one of a subfamily of PPARs, particularly mirrors glucose lowering activity. We prepared thiazolidinediones featuring benzoxazole moiety for subtype selective PPAR$\gamma$ activators. 5-[4-[2-(Benzoxazol-2-yl-alkylamino)ethoxy]benzyl]thiazolidine-2,4-diones have been prepared by Mitsunobu reaction of benzoxazolylalkylaminoethanol 8 and hydroxybenzylthiazolidinedione 6 and their activities were evaluated. Most compounds tested were identified as potent PPAR$\gamma$ agonists.

Keywords

References

  1. Aronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J. W., Mathisen, A. L., and Schneider, R. L., Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care, 23, 1605-1611(2000) https://doi.org/10.2337/diacare.23.11.1605
  2. Berger, J. and Moller, D. E., The mechanisms of action of PPARs. Ann. Rev. Med., 53, 409-435 (2002) https://doi.org/10.1146/annurev.med.53.082901.104018
  3. Cantello, B. C., Cawthorne, M. A., Cottam, G. P., Duff, P. T., Haigh, D., Hindley, R. M., Lister, C. A., Snith, S. A., and Thurlby P. L., [[Omega-(heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem., 37, 3977-3985 (1994) https://doi.org/10.1021/jm00049a017
  4. Dahl-Jorgensen, K. and Brinchmann-Hansen, O., Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. Br. Med.J., 293, 1195-1199 (1986) https://doi.org/10.1136/bmj.293.6556.1195
  5. Defronzo, R. A., Bonadonna, R. C., and Ferrannini, E., Pathogenesis of NIDDM. A balanced overview. Diabetes Care, 15, 318-368 (1992) https://doi.org/10.2337/diacare.15.3.318
  6. Defronzo, R. A., Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes, 37, 667-687 (1988) https://doi.org/10.2337/diab.37.6.667
  7. Desvergne, B. and Wahli, W., Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endcrine Rev., 20, 649-688 (1999) https://doi.org/10.1210/er.20.5.649
  8. Feldt-Rasmussen, B., Mathisesn, E., and Deckert, T., Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet, 2, 1300-1304 (1986)
  9. Holman, R. R. and Turner, R. C., Textbook of Diabetes; Pickup, J. C., Williams, G. Eds.; Blackwell Scientofic Publications: London, pp 462-476 (1991)
  10. Ibrahimi, A., Teboul, L., Gaillard, D., Amir, E. Z., Ailhaud, G., Young, P., Cawthorne, M. A., and Grimardi, P. A., Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol. Pharmacol., 46, 1070-1076 (1994)
  11. Kersten, S., Desvergne, B., and Wahli, W., Roles of PPARs in health and disease. Nature, 405, 421-424 (2000) https://doi.org/10.1038/35013000
  12. Kletzien, R. F., Clark, S. D., and Ulrich, R. G., Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol., 41, 393-398 (1992)
  13. Lehmann, J. M., Moorre, L. B., Smith-Oliver,T A, Wilkinson, W. O., Wilson, T. M., and Kliewer, S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem., 270, 12953-12956 (1995) https://doi.org/10.1074/jbc.270.22.12953
  14. Martin, G., Schoonjans, K., Staels, B., and Aurex, J., $PPAR{\gamma}$ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atheroscrelosis, 137 (Suppl), S75-S80 (1998) https://doi.org/10.1016/S0021-9150(97)00315-8
  15. Morita, H., Mori, H., and Kobayashi, Y., Process for the production of a thiazolidine derivative. GB 2324089A (1998)
  16. Ruderman, N. B. and Scheneider, S. H., Diabetes, exercise, and atherosclerosis. Diabetes Care, 15 (Suppl. 4), 1787-1793 (1992) https://doi.org/10.2337/diacare.15.11.1787
  17. Sohda, T., Momose, Y., Meguro, K., Kawamatsu, Y., Sugiyama, Y., and Ikeda, H., Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneim.-Forsch., 40, 37-42 (1990)
  18. Yoshioka, T., Fujita, T., Kanai, T., Aizawa, Y., Kurumada, T., Hasegawa, K., and Horikoshi, H., Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J. Med. Chem., 32,421-428 (1989) https://doi.org/10.1021/jm00122a022